Tate

Tate Biotherapeutics is a pre-clinical stage biotechnology company focused on developing a novel class of 'living medicines' for the treatment of solid tumors. The company utilizes its proprietary T-SURE (Tumor-Specific Uniform Response Enhancement) platform to engineer attenuated Salmonella typhimurium that selectively colonize and proliferate within the tumor microenvironment. These engineered bacteria are designed to deliver therapeutic payloads, such as Interleukin-12 (IL-12), directly to the tumor site to stimulate a localized immune response. By leveraging the natural tumor-homing abilities of bacteria, Tate Biotherapeutics aims to overcome the limitations of systemic toxicity and poor penetration associated with traditional cancer therapies. The company's approach represents a promising frontier in immunotherapy for hard-to-treat solid cancers.